# MARK1

## Overview
MARK1 (microtubule affinity regulating kinase 1) is a gene that encodes a serine/threonine kinase involved in the regulation of microtubule dynamics. The protein product of MARK1 plays a pivotal role in cellular processes by phosphorylating microtubule-associated proteins, thereby modulating their interaction with microtubules and influencing microtubule stability and dynamics. This kinase is crucial for maintaining cellular polarity, particularly in neuronal cells, where it affects neuronal differentiation and axonal transport. Structurally, MARK1 contains several domains, including an N-terminal Ser/Thr kinase domain, a ubiquitin-associated domain, and a C-terminal kinase-associated-1 domain, which are essential for its regulatory functions and interactions (Emptage2018Structural; Emptage2017Molecular). MARK1's activity is regulated through autoinhibition and interactions with phospholipid membranes, highlighting its complex regulatory mechanisms (Emptage2018Structural). The gene's dysregulation has been implicated in various diseases, including cancer and neurodegenerative disorders, underscoring its clinical significance (p&gt; Zheng2020&lt; MiR4865p; Matenia2009The).

## Structure
MARK1 (microtubule affinity regulating kinase 1) is a serine/threonine kinase involved in microtubule dynamics. The protein structure of MARK1 includes several distinct domains: an N-terminal Ser/Thr kinase domain, a ubiquitin-associated (UBA) domain, a linker region, and a C-terminal kinase-associated-1 (KA1) domain (Emptage2017Molecular). The KA1 domain is involved in autoinhibition and can bind to anionic phospholipid membranes, which reverses this inhibition (Emptage2018Structural).

The crystal structure of MARK1 reveals that the KA1 domain interacts with both the N- and C-lobes of the kinase domain, engaging in intramolecular interactions that are crucial for maintaining autoinhibition (Emptage2018Structural). The KA1 domain is characterized by a four-stranded beta-sheet flanked by two alpha helices and is conserved across the CAMKL family (Emptage2018Structural).

The UBA domain of MARK1 is well-defined and conserved, primarily interacting with the N-lobe of the catalytic domain through hydrophobic interactions (Marx2006Structural). Structural variations between MARK1 and its isoform MARK2 include differences in the activation loop and the catalytic loop, which are influenced by specific amino acid exchanges (Marx2006Structural). MARK1 can exist in different isoforms due to alternative splicing, which may affect its structure and function (Marx2006Structural).

## Function
MARK1 (microtubule affinity regulating kinase 1) is a serine/threonine kinase that plays a crucial role in regulating microtubule dynamics in healthy human cells. It phosphorylates microtubule-associated proteins (MAPs) such as tau, MAP2, and MAP4, which leads to their dissociation from microtubules. This phosphorylation reduces the affinity of these proteins for microtubules, resulting in microtubule destabilization and increased dynamics, which are essential for various cellular processes, including cell shape regulation, intracellular transport, and cell polarity (Marx2010Structure; Drewes1997MARK).

MARK1 is involved in maintaining cellular polarity and is particularly important in neuronal cells, where it contributes to processes like neuronal differentiation and axonal transport. By phosphorylating tau, MARK1 facilitates the detachment of tau from microtubules, which is crucial for efficient axonal transport and the prevention of transport inhibition (Wu2017Regulation; Mandelkow2004MARKPAR1).

In terms of cellular localization, MARK1 is active in the cytoplasm and is associated with the cytoskeleton, where it exerts its effects on microtubule stability and organization (Marx2010Structure). This activity is vital for maintaining normal cellular functions and ensuring proper intracellular transport and cell signaling.

## Clinical Significance
Alterations in the expression or function of the MARK1 gene have been implicated in several diseases. In endometrial carcinoma, miR-486-5p is significantly up-regulated and targets MARK1, promoting cell proliferation, migration, and invasion, suggesting its role as an oncogene in this cancer type (p&gt; Zheng2020&lt; MiR4865p). 

MARK1 is also associated with neurological disorders. Overexpression of MARK1 in the prefrontal cortex has been observed in patients with autism, indicating a potential link to changes in neuronal dendrite function (Matenia2009The). In Alzheimer's disease, MARK1 is involved in the phosphorylation of tau protein, which leads to microtubule destabilization and contributes to the formation of neurofibrillary tangles, a hallmark of the disease (Matenia2009The; Drewes1997MARK).

Additionally, MARK1 has been identified as a substrate of leucine-rich repeat kinase 2 (LRRK2), which is associated with Parkinson's disease. The interaction between LRRK2 and MARK1 may influence cytoskeletal dynamics and cellular morphology, potentially contributing to neurodegenerative processes (Krumova2015Chemical). These findings highlight the clinical significance of MARK1 in various pathological conditions.

## Interactions
MARK1 (microtubule affinity regulating kinase 1) is involved in several protein interactions that influence its function and regulation. MARK1 interacts with the AP-2 adaptor complex of clathrin-coated vesicles (CCVs), which is crucial for vesicle trafficking. This interaction is mediated through a discontinuous epitope within the catalytic domain of MARK1, with the strongest binding observed in a segment overlapping the activation loop peptide (Schmitt‐Ulms2009Interactions). MARK1 also colocalizes with b2-adaptin and clathrin, indicating its vesicular distribution (Schmitt‐Ulms2009Interactions).

The KA1 domain of MARK1 plays a role in autoinhibition by interacting with the kinase-UBA fragment. This interaction is weak and driven by electrostatic forces, allowing for potential modulation of MARK1 activity through membrane binding (Emptage2017Molecular). The KA1 domain can inhibit MARK1 activity, and its autoinhibitory effect can be relieved by membrane interactions, suggesting a mechanism for activation through phospholipid binding (Emptage2017Molecular).

MARK1 is also involved in phosphorylating microtubule-associated proteins (MAPs) such as tau, MAP2, and MAP4, which affects microtubule stability and dynamics (Drewes1997MARK). These interactions highlight MARK1's role in cellular processes like microtubule dynamics and vesicle trafficking.


## References


[1. (Emptage2018Structural) Ryan P. Emptage, Mark A. Lemmon, Kathryn M. Ferguson, and Ronen Marmorstein. Structural basis for mark1 kinase autoinhibition by its ka1 domain. Structure, 26(8):1137-1143.e3, August 2018. URL: http://dx.doi.org/10.1016/j.str.2018.05.008, doi:10.1016/j.str.2018.05.008. This article has 16 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.str.2018.05.008)

[2. (Drewes1997MARK) Gerard Drewes, Andreas Ebneth, Ute Preuss, Eva-Maria Mandelkow, and Eckhard Mandelkow. Mark, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell, 89(2):297–308, April 1997. URL: http://dx.doi.org/10.1016/S0092-8674(00)80208-1, doi:10.1016/s0092-8674(00)80208-1. This article has 1039 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/S0092-8674(00)80208-1)

[3. (Wu2017Regulation) Youjun Wu and Erik E. Griffin. Regulation of Cell Polarity by PAR-1/MARK Kinase, pages 365–397. Elsevier, 2017. URL: http://dx.doi.org/10.1016/bs.ctdb.2016.11.001, doi:10.1016/bs.ctdb.2016.11.001. This article has 38 citations.](https://doi.org/10.1016/bs.ctdb.2016.11.001)

[4. (Krumova2015Chemical) Petranka Krumova, Lauran Reyniers, Marc Meyer, Evy Lobbestael, Daniela Stauffer, Bertran Gerrits, Lionel Muller, Sjouke Hoving, Klemens Kaupmann, Johannes Voshol, Doriano Fabbro, Andreas Bauer, Giorgio Rovelli, Jean‐Marc Taymans, Tewis Bouwmeester, and Veerle Baekelandt. Chemical genetic approach identifies microtubule affinity‐regulating kinase 1 as a leucine‐rich repeat kinase 2 substrate. The FASEB Journal, 29(7):2980–2992, April 2015. URL: http://dx.doi.org/10.1096/fj.14-262329, doi:10.1096/fj.14-262329. This article has 15 citations.](https://doi.org/10.1096/fj.14-262329)

[5. (Mandelkow2004MARKPAR1) Eva-Maria Mandelkow, Edda Thies, Bernhard Trinczek, Jacek Biernat, and Eckard Mandelkow. Mark/par1 kinase is a regulator of microtubule-dependent transport in axons. The Journal of Cell Biology, 167(1):99–110, October 2004. URL: http://dx.doi.org/10.1083/jcb.200401085, doi:10.1083/jcb.200401085. This article has 185 citations.](https://doi.org/10.1083/jcb.200401085)

[6. (Emptage2017Molecular) Ryan P. Emptage, Mark A. Lemmon, and Kathryn M. Ferguson. Molecular determinants of ka1 domain-mediated autoinhibition and phospholipid activation of mark1 kinase. Biochemical Journal, 474(3):385–398, January 2017. URL: http://dx.doi.org/10.1042/bcj20160792, doi:10.1042/bcj20160792. This article has 20 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1042/bcj20160792)

[7. (Schmitt‐Ulms2009Interactions) Gerold Schmitt‐Ulms, Dorthe Matenia, Gerard Drewes, and Eva‐Maria Mandelkow. Interactions of map/microtubule affinity regulating kinases with the adaptor complex ap‐2 of clathrin‐coated vesicles. Cell Motility, 66(8):661–672, June 2009. URL: http://dx.doi.org/10.1002/cm.20394, doi:10.1002/cm.20394. This article has 9 citations.](https://doi.org/10.1002/cm.20394)

[8. (Matenia2009The) Dorthe Matenia and Eva-Maria Mandelkow. The tau of mark: a polarized view of the cytoskeleton. Trends in Biochemical Sciences, 34(7):332–342, July 2009. URL: http://dx.doi.org/10.1016/j.tibs.2009.03.008, doi:10.1016/j.tibs.2009.03.008. This article has 176 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.tibs.2009.03.008)

[9. (Marx2006Structural) Alexander Marx, Chanakya Nugoor, Jens Müller, Saravanan Panneerselvam, Thomas Timm, Matthias Bilang, Efstratios Mylonas, Dmitri I. Svergun, Eva-Maria Mandelkow, and Eckhard Mandelkow. Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (mark) 1 and mark2. Journal of Biological Chemistry, 281(37):27586–27599, September 2006. URL: http://dx.doi.org/10.1074/jbc.M604865200, doi:10.1074/jbc.m604865200. This article has 69 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M604865200)

[10. (Marx2010Structure) A. Marx, C. Nugoor, S. Panneerselvam, and E. Mandelkow. Structure and function of polarity‐inducing kinase family mark/par‐1 within the branch of ampk/snf1‐related kinases. The FASEB Journal, 24(6):1637–1648, January 2010. URL: http://dx.doi.org/10.1096/fj.09-148064, doi:10.1096/fj.09-148064. This article has 105 citations.](https://doi.org/10.1096/fj.09-148064)